Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt No Debt
PGNX's Cash to Debt is ranked higher than
91% of the 902 Companies
in the Global Biotechnology industry.

( Industry Median: 83.08 vs. PGNX: No Debt )
PGNX' s 10-Year Cash to Debt Range
Min: 65   Max: No Debt
Current: No Debt

Equity to Asset 0.76
PGNX's Equity to Asset is ranked higher than
79% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. PGNX: 0.76 )
PGNX' s 10-Year Equity to Asset Range
Min: 0.31   Max: 0.98
Current: 0.76

0.31
0.98
Interest Coverage No Debt
PGNX's Interest Coverage is ranked higher than
99% of the 408 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. PGNX: No Debt )
PGNX' s 10-Year Interest Coverage Range
Min: 2   Max: 9999.99
Current: No Debt

2
9999.99
F-Score: 4
Z-Score: 1.31
M-Score: -2.97
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -546.68
PGNX's Operating margin (%) is ranked higher than
58% of the 790 Companies
in the Global Biotechnology industry.

( Industry Median: -71.36 vs. PGNX: -546.68 )
PGNX' s 10-Year Operating margin (%) Range
Min: -1033.33   Max: 35.35
Current: -546.68

-1033.33
35.35
Net-margin (%) -541.49
PGNX's Net-margin (%) is ranked higher than
58% of the 790 Companies
in the Global Biotechnology industry.

( Industry Median: -59.60 vs. PGNX: -541.49 )
PGNX' s 10-Year Net-margin (%) Range
Min: -1016.67   Max: 33.31
Current: -541.49

-1016.67
33.31
ROE (%) -53.90
PGNX's ROE (%) is ranked higher than
61% of the 812 Companies
in the Global Biotechnology industry.

( Industry Median: -20.84 vs. PGNX: -53.90 )
PGNX' s 10-Year ROE (%) Range
Min: -135.89   Max: 22.17
Current: -53.9

-135.89
22.17
ROA (%) -37.17
PGNX's ROA (%) is ranked higher than
64% of the 890 Companies
in the Global Biotechnology industry.

( Industry Median: -17.36 vs. PGNX: -37.17 )
PGNX' s 10-Year ROA (%) Range
Min: -358.82   Max: 20.82
Current: -37.17

-358.82
20.82
ROC (Joel Greenblatt) (%) -1781.19
PGNX's ROC (Joel Greenblatt) (%) is ranked higher than
61% of the 862 Companies
in the Global Biotechnology industry.

( Industry Median: -247.50 vs. PGNX: -1781.19 )
PGNX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1781.19   Max: 773.29
Current: -1781.19

-1781.19
773.29
Revenue Growth (%) -16.40
PGNX's Revenue Growth (%) is ranked higher than
66% of the 624 Companies
in the Global Biotechnology industry.

( Industry Median: -1.80 vs. PGNX: -16.40 )
PGNX' s 10-Year Revenue Growth (%) Range
Min: -55.7   Max: 73.2
Current: -16.4

-55.7
73.2
EBITDA Growth (%) -28.60
PGNX's EBITDA Growth (%) is ranked higher than
60% of the 598 Companies
in the Global Biotechnology industry.

( Industry Median: -10.50 vs. PGNX: -28.60 )
PGNX' s 10-Year EBITDA Growth (%) Range
Min: -28.6   Max: 51.4
Current: -28.6

-28.6
51.4
EPS Growth (%) -29.20
PGNX's EPS Growth (%) is ranked higher than
63% of the 631 Companies
in the Global Biotechnology industry.

( Industry Median: -12.60 vs. PGNX: -29.20 )
PGNX' s 10-Year EPS Growth (%) Range
Min: -73.5   Max: 221.4
Current: -29.2

-73.5
221.4
» PGNX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2013

PGNX Guru Trades in Q2 2013

Jim Simons 103,089 sh (New)
Murray Stahl 67,200 sh (+3.07%)
Paul Tudor Jones 2,342,388 sh (unchged)
» More
Q3 2013

PGNX Guru Trades in Q3 2013

Steven Cohen 32,206 sh (New)
Louis Moore Bacon 50,000 sh (New)
Jim Simons 280,100 sh (+171.71%)
Murray Stahl 67,200 sh (unchged)
Paul Tudor Jones 2,342,388 sh (unchged)
» More
Q4 2013

PGNX Guru Trades in Q4 2013

Louis Moore Bacon 95,000 sh (+90%)
Paul Tudor Jones 2,342,795 sh (+0.02%)
Murray Stahl 67,200 sh (unchged)
Jim Simons Sold Out
Steven Cohen Sold Out
» More
Q1 2014

PGNX Guru Trades in Q1 2014

Steven Cohen 28,878 sh (New)
Murray Stahl 67,200 sh (unchged)
Louis Moore Bacon Sold Out
Paul Tudor Jones 2,342,388 sh (-0.02%)
» More
» Details

Insider Trades

Latest Guru Trades with PGNX



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 3.20
PGNX's P/B is ranked higher than
82% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 5.80 vs. PGNX: 3.20 )
PGNX' s 10-Year P/B Range
Min: 1.08   Max: 16.48
Current: 3.2

1.08
16.48
P/S 39.68
PGNX's P/S is ranked higher than
65% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 18.96 vs. PGNX: 39.68 )
PGNX' s 10-Year P/S Range
Min: 1.92   Max: 62.55
Current: 39.68

1.92
62.55
EV-to-EBIT -6.06
PGNX's EV-to-EBIT is ranked higher than
77% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. PGNX: -6.06 )
PGNX' s 10-Year EV-to-EBIT Range
Min: 9.8   Max: 72
Current: -6.06

9.8
72
Current Ratio 23.85
PGNX's Current Ratio is ranked higher than
97% of the 894 Companies
in the Global Biotechnology industry.

( Industry Median: 4.02 vs. PGNX: 23.85 )
PGNX' s 10-Year Current Ratio Range
Min: 2.67   Max: 32.92
Current: 23.85

2.67
32.92
Quick Ratio 23.85
PGNX's Quick Ratio is ranked higher than
97% of the 894 Companies
in the Global Biotechnology industry.

( Industry Median: 3.76 vs. PGNX: 23.85 )
PGNX' s 10-Year Quick Ratio Range
Min: 2.67   Max: 32.92
Current: 23.85

2.67
32.92

Valuation & Return

vs
industry
vs
history
Price/Net Cash 5.70
PGNX's Price/Net Cash is ranked higher than
89% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 63.00 vs. PGNX: 5.70 )
PGNX' s 10-Year Price/Net Cash Range
Min: 1.59   Max: 22.41
Current: 5.7

1.59
22.41
Price/Net Current Asset Value 5.60
PGNX's Price/Net Current Asset Value is ranked higher than
88% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 43.44 vs. PGNX: 5.60 )
PGNX' s 10-Year Price/Net Current Asset Value Range
Min: 1.54   Max: 20.5
Current: 5.6

1.54
20.5
Price/Tangible Book 4.90
PGNX's Price/Tangible Book is ranked higher than
80% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 8.86 vs. PGNX: 4.90 )
PGNX' s 10-Year Price/Tangible Book Range
Min: 1.22   Max: 13.73
Current: 4.9

1.22
13.73
Price/Median PS Value 3.60
PGNX's Price/Median PS Value is ranked higher than
66% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 1.90 vs. PGNX: 3.60 )
PGNX' s 10-Year Price/Median PS Value Range
Min: 0.2   Max: 5.03
Current: 3.6

0.2
5.03
Earnings Yield (Greenblatt) 5.20
PGNX's Earnings Yield (Greenblatt) is ranked higher than
69% of the 399 Companies
in the Global Biotechnology industry.

( Industry Median: 4.70 vs. PGNX: 5.20 )
PGNX' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1.4   Max: 10.2
Current: 5.2

1.4
10.2
Forward Rate of Return (Yacktman) -15.58
PGNX's Forward Rate of Return (Yacktman) is ranked higher than
71% of the 740 Companies
in the Global Biotechnology industry.

( Industry Median: -10.93 vs. PGNX: -15.58 )
PGNX' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -19.6   Max: -9
Current: -15.58

-19.6
-9

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:PGP.Germany
Progenics Pharmaceuticals, Inc. is engaged in the research and development of biotechnology product candidates in the areas of oncology, virology, supportive care, and gastroenterology. The company offers RELISTOR, a subcutaneous injection for the treatment of opioid induced constipation in patients with advanced illnesses, such as cancer. It is also developing RELISTOR, a subcutaneous injection for the treatment of OIC in patients with non-cancer pain; and RELISTOR-Oral, which has completed Phase III testing for the treatment of OIC in patients with non-cancer pain. The company's principal product candidate under development is PSMA ADC, which is in Phase I trial in men with advanced prostate cancer. PSMA ADC is an antibody-drug conjugate that targets prostate specific membrane antigen, a protein found on the surface of prostate cancer tumor cells, as well as on the neovasculature of various other types of solid tumors. In addition, the company is developing PI3K, a pre-clinical stage novel multiplex phosphoinositide 3-kinase inhibitor for blocking signaling pathways that are critical in the growth of aggressive cancers. It has license agreement with Salix Pharmaceuticals, Inc. for the development and commercialization of RELISTOR around the globe other than Japan.
» More Articles for PGNX

Headlines

Articles On GuruFocus.com
Weekly CEO Buys Highlight: CVRR, HBAN, VVTV, SXCP, PGNX Jan 26 2013 
Weekly CEO Buys Highlight: CVRR, HBAN, VVTV, SXCP, PGNX Jan 27 2013 
Weekly CEO Buys Highlight: SUSP, ROVI, ZLC, MDW, PGNX Oct 01 2012 
5 Stocks That Dropped the Most Since Gurus Bought Them Sep 13 2012 
Dendreon Could Push Higher If New Drug Trials Succeed Apr 23 2012 
Progenics Pharmaceuticals Inc. (PGNX) CEO Paul J Maddon buys 5,000 Shares Dec 01 2010 
Progenics Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 08 2010 
Progenics Pharmaceuticals Inc. (PGNX) CEO Paul J Maddon buys 5,000 Shares Nov 02 2010 
Progenics Pharmaceuticals Inc. (PGNX) CEO Paul J Maddon buys 5,000 Shares Oct 04 2010 
Progenics Pharmaceuticals Inc. (PGNX) CEO Paul J Maddon buys 5,000 Shares Sep 02 2010 

More From Other Websites
Key Stocks Seeing Insider Buying This Week Jul 26 2014
Progenics (PGNX) Shares March Higher, Can It Continue? Jul 22 2014
An Inefficient Stock Market Will Catch Up To Progenics Jul 21 2014
Progenics-Salix Up on Encouraging Relistor News Jul 15 2014
Biotechs, social stocks weak after Yellen warning Jul 15 2014
Progenics Pharmaceuticals, Inc. (PGNX) in Focus: Stock Rises 8.5% Jul 15 2014
PROGENICS PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jul 14 2014
FDA Office of Drug Evaluation III Approves Salix's Request that the FDA Approve the RELISTOR®... Jul 14 2014
Midday movers: Citigroup, Newmont Mining & More Jul 14 2014
Progenics Holds Conference Call This Morning on FDA Appeal Response Regarding Relistor(R) sNDA for... Jul 14 2014
UPDATE: Salix, Progenics Report FDA Office Of Drug Evaluation III Approves Salix Request For FDA... Jul 14 2014
Progenics Holds Conference Call This Morning on FDA Appeal Response Regarding Relistor(R) sNDA for... Jul 14 2014
FDA Office of Drug Evaluation III Approves Salix’s Request that the FDA Approve the RELISTOR®... Jul 14 2014
Another good find in specialty pharma Jul 03 2014
PROGENICS PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers,... Jun 18 2014
What Does A Positive Adcom Mean For Progenics And Salix? Jun 17 2014
[$$] Two Undervalued Biopharmas to Buy Now Jun 13 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide